New Documentary HOMEMADE follows decorated veterans struggle with PTSD, TBI, drug addiction and subsequent recovery


Official movie poster – HOMEMADE

Film Premieres in Select Cities Nationwide Veterans Day Weekend

HOMEMADE examines the culture of treating symptoms instead of the root cause, and the disconnect between medical care and true wellness”

— Danielle Bernstein, Producer/Editor/Co-Director of HOMEMADE

WASHINGTON DC , UNITED STATES, October 22, 2019 /EINPresswire.com/ — A new documentary film being released Veteran’s Day weekend is likely to ignite renewed conversations about how best to care for our returning vets and their families.

HOMEMADE is the cinematic and profoundly intimate journey with decorated Force Reconnaissance Marine Adam Sorensen as he navigates civilian life and the effects of Post Traumatic Stress, Traumatic Brain Injury, and crippling addiction on his marriage, family, and work. Heart-wrenching, winding, on-going (the filmmakers following Adam and his family for six years, and the film took seven years total to complete) and unflinching, the film uncovers a conflict between the American ideals of success and personal well-being.

HOMEMADE will screen in select markets across America Veterans Day weekend, beginning in Portland Oregon Saturday, November 9th and wrapping up Tuesday, November 12th in Washington DC. Several screenings will be held in smaller heartland communities that have a large veteran population.

Each screening will be followed by a panel discussion and question and answer session featuring local veteran’s advocacy and support groups and addiction specialists. In select markets, Adam Sorensen, the highly decorated Marine veteran whose marriage, invisible wounds and struggles with PTSD, TBI, and addiction the film follows in gripping detail will appear, as will HOMEMADE documentary filmmakers Jason Maris and Danielle Bernstein.

“Ultimately, HOMEMADE is a story of survival and resilience unveiling the complexity and scope of these challenges as Adam and his family navigate life after combat,” said Bernstein. “Through the experiences of Adam, his wife Victoria, and their families, HOMEMADE examines the culture of treating symptoms instead of the root cause, and the disconnect between medical care and true wellness. We look at things like the continuity of care, the epidemic of over-prescription in both military and civilian care, and the stereotypes of injured combat veterans in an up-close and personal way that audiences have never seen before.”

HOMEMADE’s filmmakers say they aim to close what they call “the empathy gap” between civilian and military communities, start productive dialogues about the challenge of transition from active duty military to retired, and to provide tools that help viewers take action.

Director Jason Maris was inspired to make this film after working for over 20 years as a freelance recruitment photographer for the United States Marine Corps advertising agency, JWT. Since his imagery has been in circulation, over 600,000 men and women have signed up to serve. “I feel a great responsibility to each and every Marine. After 9/11 I wanted to help those returning from combat and felt an increasing urgency to understand what was happening to families and how hidden wounds were playing out over time.”

There are an estimated 1.1 million military caregivers who are family members, friends, or acquaintances (Hidden Heroes) in the United States caring for post-9/11 veterans. They tend to be younger, caring for a younger individual with a mental health or substance use condition, employed, and not connected to a support network.

Studies show that at least 20% of Iraq and Afghanistan veterans have PTSD and/or Depression. The number climbs higher when combined with traumatic brain injury (TBI). 19% of veterans may have traumatic brain injury (TBI) and 50% of those with PTSD do not seek treatment.

HOMEMADE screened earlier this month at the Nashville Film Festival. Middle Tennessee State University, which sponsors the festival, oversaw a frank and often emotional panel discussion after the screening that included documentary subject, Adam Sorensen.

Retired U.S. Army Lt. Gen. Keith Huber, the university’s senior adviser for veterans and leadership initiatives who served 38 years in the military moderated the discussion. Huber applauded the filmmakers on “an incredibly accurate documentary film that unflinchingly highlighted the challenges that combat veterans can face after multiple deployments, serious physical and mental injuries and a resulting disconnect from civilian life that can be extremely difficult to bridge”.

More coverage of the Nashville Film Festival screening event is available here: https://www.dnj.com/story/news/local/schools/mtsu/2019/10/12/nashville-film-festival-veterans-deployment-mtsu-charlie-hazel-daniels-center-ptsd-opioid-addiction/3957878002/

For a complete listing of HOMEMADE Veteran’s Day weekend screenings followed by panel discussions and Q&A’s and information on how to get tickets, go to https://www.homemadethefilm.com/find-a-screening

To speak with HOMEMADE filmmakers Jason Maris or Danielle Bernstein or HOMEMADE’s documentary subject, U.S. Marine veteran Adam Sorenson, or to request event tickets or screener links, contact

Burke Allen
Allen Media Strategies
+1 703-589-8960
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Official movie trailer – HOMEMADE


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.



Source

Tosk’s Successful New Chemotherapy Side Effect Prevention Drug Discovered Using Fruit Flies


Drug developer Tosk, Inc.,

For more than a century, the common fruit fly has been critical to scientists.

The fruit fly has played a critical role in Tosk’s innovative research

Innovative biotech’s TK-90 drug prevented mucositis, the ulceration of the GI tract caused by standard cancer therapies, in Phase 2a, placebo-cøntrolled, trial.

Those taking TK-90 were nearly mucositis free based on two recognized measures of the condition, while the placebo group suffered, on average, significant mucositis after four weeks.”

— Dr. William Garland, Vice President, R&D, Tosk, Inc.

MOUNTAIN VIEW, CALIFORNIA, USA, October 15, 2019 /EINPresswire.com/ — Tosk, Inc.’s, recent success in its Phase 2a, placebo-controlled, clinical study of TK-90 in head and neck cancer patients, validates the effectiveness of the company’s use of fruit flies as a powerful discovery tool in its research, according to Vice President of Research and Development, Dr. Bill Garland.
TK-90 demonstrated prevention of mucositis, the ulceration of the GI tract caused by front line cancer therapies such as methotrexate and radiation. The toxic effects of such treatments are painful and can be life threatening. They also often limit the dosage and duration of treatment.
“Half the patients in the trial were given TK-90 along with chemotherapy and the other half a placebo with the same chemotherapy,” according to Dr. Garland. “Those taking TK-90 were nearly mucositis free based on two recognized measures of the condition, while the placebo group suffered, on average, significant mucositis after four weeks.”
The clinical study confirmed the results from an earlier test in 25 patients. The study results were so positive, Dr. Garland stated, that they suggest that TK-90 has the potential to become a standard part of cancer therapy for treatments that cause mucositis in the GI tract.
“Tosk has two patented technologies that use fruit flies as models to screen potential drug candidates,” Garland noted. “We use the flies in our research because nearly 70 percent of human disease-related genes have analogs in the fly genome. With flies, discovery can be done quickly and cost effectively in a whole animal model. The fact that TK-90 is the first drug discovered in a fly to successfully complete a clinical study bodes well for other drugs in our pipeline.”
Tosk has three other proprietary drugs in development. TK-39 is designed to prevent the cardiotoxicity caused by widely-used chemotherapies, such as doxorubicin. TK-88 Is designed to block kidney toxicity, peripheral neuropathy, and hearing loss caused by platinum-based drugs such as cisplatin. TK-kRAS is being developed to block the activity of proteins produced by mutant kRAS genes that drive tumor growth in as many as 30 percent of all cancers. This development has been funded in part by a $2 million grant from the National Cancer Institute.

Tosk, Inc. is a privately held biopharmaceutical company that discovers and develops new drugs to improve outcomes for cancer patients by preventing the adverse side effects of existing, widely used cancer therapies and by blocking the proteins produced by cancer genes.

Brian Frenzel
Tosk, Inc.
+1 408-245-6838
email us here

The Tosk Challenge: New Solutions for Oncology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.



Source

Animal Generic Drug Market 2019 Global Analysis, Growth, Size, Share, Trends, Forecast to 2024


Global Animal Generic Drug Market 2019 Analysis (By Segment, Product And Applications) And Forecasts To 2024

PUNE, MAHARASHTRA, INDIA, October 9, 2019 /EINPresswire.com/ — Animal Generic Drug Industry

Description

Global Animal Generic Drug Industry 2019 Market Research Report Provide The Details About Industry Overview And Analysis About Manufacturing Cost Structure, Revenue, Gross Margin, Consumption Value And Sale Price, Major Manufacturers, Distributors, Industry Chain Structure, New Project Swot Analysis With Development Trends And Forecasts 2024.

This report studies the Animal Generic Drug market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Animal Generic Drug market by product type and application/end industries.Apart from this, the information about the Animal Generic Drug market is provided based on its highly competitive partners, key players, and their market revenue in the years. This includes numbers of global, regional, and country-specific players who are making the Animal Generic Drug market highly fragmented.

The focus is also on the sales of products, product revenues, as well as product categories, which is gaining the maximum traction. In this way, the report suggests about the effectiveness of the Animal Generic Drug market with its growth during the 2025 forecast period. The other attributes of the market are also analyzed extensively across a broad array of developments, which creates a solid hold of the market for the forthcoming. The study of the market has been taken place during 2019, the base year and the forecast period stretches till 2025.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/4512360-2018-2025-animal-generic-drug-report-on-global

The major players in global and United States market, including 

Bayer Animal Health 
Bimeda 
Boehringer Ingelheim 
Ceva Sante Animale 
Elanco 
Huvepharma 
Merck 
Norbrook 
Perrigo 
Vetoquinol 
Zoetis 

On the basis of product, the market is primarily split into 
Pharmaceuticals 
Biologicals 
Medicinal Feed Additives 

On the basis on the end users/application, this report covers 
Broilers 
Pigs 
Cows 
Others

Drivers & Constraints

The Animal Generic Drug market remains amalgamated with the incidence of foremost players who keep contributing to the market’s growth significantly t. The report studies the value, volume trends, and the pricing antiquity of the market so that it could predict maximum growth in the future. Besides, various latent growth factors, restraints, and opportunities are also evaluated for the advanced study and suggestions of the market over the forecast period.

Regional Description

The report of the Animal Generic Drug market provides competitive strategies over various regions on a global note, where key players tend to maximize profits through partnerships into several regions. The regional report of the Animal Generic Drug market aims at assessing the market size and future growth potential across the mentioned regions. The report makers cover the regions such as North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa with the prediction of future market expansion. The study of the Animal Generic Drug market is done broadly following all these regions to embrace outlook, latest trends, and prospects in the given review period of 2019-2025.

Continued…        

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=4512360    

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
08411985042
email us here


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.



Source